title: Pazopanib for the treatment of soft-tissue sarcoma.
abstract: Pazopanib is a multikinase inhibitor which potently inhibits the activity of major receptor tyrosine kinases, including vascular endothelial growth factor receptor-1, vascular endothelial growth factor receptor-2, vascular endothelial growth factor receptor-3, platelet-derived growth factor receptor-a, platelet-derived growth factor receptor-a, and c-Kit. Approved by the Food and Drug Administration in 2009 in the United States for the treatment of metastatic renal cell carcinoma, pazopanib has been tested in advanced or metastatic soft-tissue sarcoma. Unlike other tyrosine kinase inhibitors, a statistically significant efficacy in phase II but also in randomized phase III studies has been shown. In comparison with sunitinib or sorafenib, pazopanib has a similar toxicity profile and is generally well tolerated. This review details the development of this new therapeutic class in the treatment of metastatic soft-tissue sarcomas.
authors.affiliation: Department of Medical Oncology, Leon Berard Center, Lyon, France.
authors.forename: Pierre
authors.initials: P
authors.lastname: Heudel
authors.forename: Philippe
authors.initials: P
authors.lastname: Cassier
authors.forename: Olfa
authors.initials: O
authors.lastname: Derbel
authors.forename: Armelle
authors.initials: A
authors.lastname: Dufresne
authors.forename: Pierre
authors.initials: P
authors.lastname: Meeus
authors.forename: Philippe
authors.initials: P
authors.lastname: Thiesse
authors.forename: Dominique
authors.initials: D
authors.lastname: Ranchère-Vince
authors.forename: Jean Yves
authors.initials: JY
authors.lastname: Blay
authors.forename: Isabelle
authors.initials: I
authors.lastname: Ray-Coquard